ARCHIVES

Phase IIb Trial of Vintafolide-Docetaxel Combination Meets Primary Endpoint of Progression-Free Survival

This article is from The Cancer Letter archive.

Vol. 37 No. 3 | March 28, 2014

Download PDF Visit The Full Archive

Related Articles

In Brief: FDA’s Burlington Moves to Wyeth-Ayerst; NAS Award to Beckman; Genetics Online

February 5, 1999

New Report On Survival Data Available From NCI

July 25, 1975

U.S., France Offer Carcinogenesis Program

February 13, 1981

Biotheraputices To Reveal Plans for Expansion

August 8, 1986

Wilding named director, Univ. of Wisconsin Cancer Center.

January 30, 2004

In Brief: Board Subcommittee Meetings On Comprehensive Centers Postponed; FDA Committee Uncharted

March 10, 1978